Oxaliplatin Fresenius Kabi Oncology

Oxaliplatin, the active ingredient in Oxaliplatin Fresenius Kabi Oncology, is a platinum compound presented as a unknown/unknown for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Fresenius Kabi Oncology as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Oxaliplatin Fresenius Kabi Oncology as a licensed, GDP‑compliant international supplier serving hospitals and oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapy agent that interferes          ​     ​  ​                                                                                          ​

- Colorectal cancer: improves survival and reduces tumour size when combined with fluorouracil and leucovorin. -   -   - "). -